# US 2025/0205192 A1 · Methods and materials for treating pancreatic diseases and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205192 A1
- Document ID: US20250205192A1
- Status: Published application
- Kind: A1
- Application number: 18/848,249
- Filed: 2023-03-31
- Published: 2025-06-26
- Earliest claimed: 2022-03-31
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Vijay P. Singh
- Web page: https://patentgrep.com/patent/US20250205192A1

## CPC

- A61K 31/365: Lactones
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This document relates to methods and materials for treating pancreatitis (e.g., chronic pancreatitis) in a mammal (e.g., a human). For example, methods for using one or more lipase inhibitors to treat a mammal having or at risk of developing pancreatitis (e.g., chronic pancreatitis) are provided.

## Claims

### Claim 1

A method for reducing adhesion in a pancreas and/or peritoneal cavity of a mammal, said method comprising administering a lipase inhibitor to said mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein said mammal has chronic pancreatitis, pancreatic cancer, or a post-operative pancreatic fistula.

### Claim 3 (depends on 1)

The method of claim 1, wherein said mammal is a human.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein said inhibitor comprises the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 6

A method for reducing fibrosis in a pancreas and/or peritoneal cavity of a mammal, said method comprising administering a lipase inhibitor to said mammal.

### Claim 7 (depends on 7)

The method of claim 7, wherein said mammal has chronic pancreatitis, pancreatic cancer, or a post-operative pancreatic fistula.

### Claim 8 (depends on 6)

The method of claim 6, wherein said mammal is a human.

### Claim 9

(canceled)

### Claim 10 (depends on 6)

The method of claim 6, wherein said inhibitor comprises the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 11

A method for reducing inflammation in a pancreas of a mammal, said method comprising administering a lipase inhibitor to said mammal.

### Claim 12 (depends on 11)

The method of claim 11, wherein said mammal has chronic pancreatitis, pancreatic cancer, or a post-operative pancreatic fistula.

### Claim 13 (depends on 11)

The method of claim 11, wherein said mammal is a human.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

The method of claim 11, wherein said inhibitor comprises the structure:
or a pharmaceutically acceptable salt thereof.

### Claim at position 16

16-24. (canceled)

### Claim 25

A method for improving survival of a mammal, said method comprising administering a lipase inhibitor to said mammal.

### Claim 26 (depends on 25)

The method of claim 25, wherein said mammal has chronic pancreatitis, pancreatic cancer, or a post-operative pancreatic fistula.

### Claim 27 (depends on 25)

The method of claim 25, wherein said mammal is a human.

### Claim 28

(canceled)

### Claim 29 (depends on 25)

The method of claim 25, wherein said inhibitor comprises the structure:
or a pharmaceutically acceptable salt thereof.
